• Revenue Cycle Management
  • COVID-19
  • Reimbursement
  • Diabetes Awareness Month
  • Risk Management
  • Patient Retention
  • Staffing
  • Medical Economics® 100th Anniversary
  • Coding and documentation
  • Business of Endocrinology
  • Telehealth
  • Physicians Financial News
  • Cybersecurity
  • Cardiovascular Clinical Consult
  • Locum Tenens, brought to you by LocumLife®
  • Weight Management
  • Business of Women's Health
  • Practice Efficiency
  • Finance and Wealth
  • EHRs
  • Remote Patient Monitoring
  • Sponsored Webinars
  • Medical Technology
  • Billing and collections
  • Acute Pain Management
  • Exclusive Content
  • Value-based Care
  • Business of Pediatrics
  • Concierge Medicine 2.0 by Castle Connolly Private Health Partners
  • Practice Growth
  • Concierge Medicine
  • Business of Cardiology
  • Implementing the Topcon Ocular Telehealth Platform
  • Malpractice
  • Influenza
  • Sexual Health
  • Chronic Conditions
  • Technology
  • Legal and Policy
  • Money
  • Opinion
  • Vaccines
  • Practice Management
  • Patient Relations
  • Careers

News: Drug makers to reveal payments to doctors


Eli Lilly and Merck announced their plans to release information concerning their payments to physicians for speaking engagements and advisory services.

Eli Lilly & Co. and Merck & Co. announced in September their plans to release information as early as next year concerning their payments to physicians for speaking engagements and advisory services.

The companies also endorsed the Physician Payments Sunshine Act, proposed by Senators Charles Grassley (R-Iowa) and Herb Kohl (D-Wisconsin), which would create a national registry of payments to physicians by medical device, supply, and pharmaceutical companies.

When contacted by Medical Economics, AstraZeneca and Pfizer issued statements in support of the legislation and greater transparency of relationships to physicians, but did not pledge to post their own payment directory. Kurt Ebenhoch, a spokesman for Abbott Laboratories, said the company supports the legislation and is studying whether it is feasible to assemble its own list. Johnson & Johnson did not respond to an inquiry.

Related Videos